Mar 17, 2022 / 12:30PM GMT
Operator
Good day, ladies and gentlemen, and welcome to the Eiger BioPharmaceuticals Conference Call to discuss the Phase 3 TOGETHER study results. (Operator Instructions) As a reminder, this call will be recorded.
I would now like introduce Mr. Sri Ryali, Chief Financial Officer of Eiger. You may begin.
Sri Ryali - Eiger BioPharmaceuticals, Inc. - CFO
Good morning, and thank you for joining us today. Welcome to our call to discuss the results of the Phase 3 TOGETHER study and our plans for peginterferon lambda for COVID-19. We issued a press release earlier this morning with detailed results from the study, which is available on our website at eigerbio.com. For today's call, we will have prepared remarks from the team, followed by Q&A. We will be using slides for the webcast, and we'll have a replay available on the Investors section of our website.
Joining me on the call today are David Cory, President and CEO; Eldon Mayer, our Chief Commercial Officer; Dr. Ingrid Choong, Senior Vice President, Clinical Development. Dr. Colin Hislop, Senior Vice
Eiger BioPharmaceuticals Inc to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda for COVID-19- Conference Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot